Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy – The non‐interventional second year follow‐up to the PRIDE study. Issue 2 (14th June 2021)

• Record Type: Journal Article
• Authors: Lang, Gabriele E.; Stahl, Andreas; Voegeler, Jessica; Quiering, Claudia; Zaremba, Laureen; Lorenz, Katrin; Spital, Georg; Liakopoulos, Sandra
• Is Part Of: Acta ophthalmologica. Volume 100:Issue 2(2022)
• Page Start: e578
• Page End: e587
• Publication Date: 2021-06-14
• Subjects: anti‐VEGF therapy -- panretinal laser photocoagulation -- proliferative diabetic retinopathy -- ranibizumab -- retinal neovascularization -- under‐treatment; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1111/aos.14907
• Languages: English
• ISSNs: 1755-375X

Abstract

Abstract: Purpose: Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non‐interventional follow‐up, performed to evaluate long‐term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real‐life conditions, prior to the approval of ranibizumab for PDR. Methods: Seventy‐three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow‐up phase and treated at the investigators discretion. Visual acuity (VA) measurements and retinal imaging were performed at Months 12, 18 and 24. Results: Mean (± SD) NV area in the ranibizumab monotherapy and combination follow‐up groups increased from 3.16 ± 4.30 mm 2 and 1.13 ± 2.78 mm 2 at Month 12 to 6.09 ± 10.79 mm 2 and 2.14 ± 4.41 mm 2 at Month 18 and 10.00 ± 17.63 mm 2 and 3.26 ± 7.05 mm 2 at Month 24, respectively. In the PRP follow‐up group, NV area declined from 5.44 ± 14.55 mm 2 at Month 12 to 1.22 ± 1.67 mm 2 at Month 18, but increased again to 4.05 ± 11.66 mm 2 at Month 24. During the observational phase, only 2 (6;8) patients in the ranibizumab (PRP;combination) follow‐up group were treated with anti‐VEGF medications, while 17 (6;10) patients received PRP laser therapy. Conclusion: Discontinuation of ranibizumab treatment in PDR patients may result in an increase of NV area and VA loss. Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control.